1. Home
  2. Labeler Index
  3. Preferred Pharmaceuticals Inc.
  4. 68788-8608
  5. Product Images: Duloxetine

Product Images Duloxetine

View Photos of Packaging, Labels & Appearance

Table of Contents

  1. Structure - 69d6387b 794f 415d 8013 23cca0a6984f 01
  2. Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 02
  3. Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 03
  4. Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 04
  5. Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 05
  6. fig 5 - 69d6387b 794f 415d 8013 23cca0a6984f 06
  7. fig 6 - 69d6387b 794f 415d 8013 23cca0a6984f 07
  8. Fig 7 - 69d6387b 794f 415d 8013 23cca0a6984f 08
  9. Figure 8 - 69d6387b 794f 415d 8013 23cca0a6984f 09
  10. Figure 9 - 69d6387b 794f 415d 8013 23cca0a6984f 10
  11. Figure 10 - 69d6387b 794f 415d 8013 23cca0a6984f 11
  12. Duloxetine Delayed-Release Cap USP 30mg - 69d6387b 794f 415d 8013 23cca0a6984f 13

Product Label Images

The following 12 images provide visual information about the product associated with Duloxetine NDC 68788-8608 by Preferred Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Structure - 69d6387b 794f 415d 8013 23cca0a6984f 01

Structure - 69d6387b 794f 415d 8013 23cca0a6984f 01

Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 02

Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 02

This text presents data on the proportion of patients experiencing relapse over time on placebo versus duloxetine treatment. The graph shows the time from randomization to relapse in days using the Kaplan-Meier estimator method. The data can be analyzed to evaluate the effectiveness of duloxetine in preventing relapse in comparison to a placebo.*

Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 03

Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 03

The data provided shows the proportion of patients experiencing a relapse over a certain period, based on the treatment received (Placebo or Duloxetine) and the time from randomization to relapse in days. The information is analyzed using the Kaplan-Meier estimator method, enabling a survival analysis to evaluate the effectiveness of the treatments in preventing relapses.*

Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 04

Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 04

Percentage of Patients Improved in a clinical trial comparing different doses of Duloxetine (60 mg and 20 mg) and Placebo in the treatment of pain. The data shows the percentage of improvement in pain from baseline for each treatment group.*

Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 05

Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 05

fig 5 - 69d6387b 794f 415d 8013 23cca0a6984f 06

fig 5 - 69d6387b 794f 415d 8013 23cca0a6984f 06

Percentage of Patients Improved in pain levels when treated with Duloxetine 60 mg, either twice daily or once daily, compared to Placebo. The percentage of improvement is displayed in the form of a table, showing the range from 0 to 100 percent.*

fig 6 - 69d6387b 794f 415d 8013 23cca0a6984f 07

fig 6 - 69d6387b 794f 415d 8013 23cca0a6984f 07

This text provides data on the percentage of patients improved with different dosages of Duloxetine and a placebo. It includes information on the percentage of pain improvement from baseline.*

Fig 7 - 69d6387b 794f 415d 8013 23cca0a6984f 08

Fig 7 - 69d6387b 794f 415d 8013 23cca0a6984f 08

This is a chart showing the percentage of pediatric patients aged 13 to 17 years old with Juvenile Fibromyalgia Syndrome achieving various levels of pain relief at week 12 in Study FM-4. The chart compares patients taking Duloxetine 60mg once daily vs. a Placebo. The pain relief is measured using the Brief Pain Inventory - Modified short Form: Adolescent Version Average Pain Score. Duloxetine-treated patients started with 30 mg once daily for 1 week and then titrated to 60 mg once daily for 12 weeks.*

Figure 8 - 69d6387b 794f 415d 8013 23cca0a6984f 09

Figure 8 - 69d6387b 794f 415d 8013 23cca0a6984f 09

Percentage of Patients Improved is shown in the chart for Placebo and Duloxetine 60/120 mg once daily. The chart represents Percent Improvement in Pain from Baseline (BOCF).*

Figure 9 - 69d6387b 794f 415d 8013 23cca0a6984f 10

Figure 9 - 69d6387b 794f 415d 8013 23cca0a6984f 10

This text shows the percentage of patients improved with Duloxetine 60 mg compared to a placebo. It indicates a 100% improvement with Duloxetine. The chart also displays the percent improvement in pain from baseline using the last observation carried forward (BOCF) method.*

Figure 10 - 69d6387b 794f 415d 8013 23cca0a6984f 11

Figure 10 - 69d6387b 794f 415d 8013 23cca0a6984f 11

Percentage of Patients Improved: 100% with placebo and duloxetine 60/120 mg once daily. The graph shows the percent improvement in pain from the baseline.*

Duloxetine Delayed-Release Cap USP 30mg - 69d6387b 794f 415d 8013 23cca0a6984f 13

Duloxetine Delayed-Release Cap USP 30mg - 69d6387b 794f 415d 8013 23cca0a6984f 13

This is a description for Duloxetine Delayed-Release Capsules USP 30mg, a generic version of Cymbalta. Each capsule contains 33.7mg of Duloxetine Hydrochloride equivalent to 30mg. It is manufactured by Lupin Limited. The warning advises storing at 25°C with excursions permitted to 15°-30°C. The capsules are blue and white with the imprint "LU Q02." The package includes information on lot number, batch number, expiration date, and instructions in Spanish. The drug is intended for the patient it was prescribed, and it is essential to keep it out of children's reach.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.